Supplementary Table 1.Comparison of longitudinal studies with long observation periods, at least three testing visits, and which administered comprehensive neuropsychological test batteries. Obs = Observation Period, TRI = Test-Retest Interval, Age at Baseline and Timepoints noted in Years Preceding Diagnosis. Red Boldface Type Refers to Significant Differences.

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Study | N | | Obs. (y) | TRI (y) | Age (y) | Timepoint of emergence of neuropsychological impairment in years preceding diagnosis | | | | | | | | | | | |
|  | NC | AD |  |  |  | -12 | -11 | -10 | -9 | -8 | -7 | -6 | -5 | -4 | -3 | -2 | -1 |
| **Baltimore Longitudinal Study of Aging** | | | | | | | | | | | | | | | | | |
| Grober et al., 2008 [1] | 822 | 92 | 15 | 2 | 79.8 ± 6.9\*\* (AD patients at baseline) |  |  |  |  |  | **VEM** EF SFlu PFlu eVIQ | **VEM** EF SFlu PFlu eVIQ | **VEM** EF SFlu PFlu eVIQ | **VEM** EF SFlu PFlu eVIQ | **VEM** **EF SFlu PFlu** eVIQ | **VEM** **EF SFlu PFlu** eVIQ | **VEM** **EF SFlu PFlu** eVIQ |
| **Bronx Aging Study** | | | | | | | | | | | | | | | | | |
| Masur et al., 1994 [2] | 253 | 64 | >4 | 1 | 78.9 ± 3.0\*\* |  |  |  |  |  |  |  |  |  | VEM NVEM WM AbReas SFlu VisSpat V-MS Lang | **VEM NVEM** **WM** AbReas **SFlu** VisSpat V-MS Lang | VEM NVEM WM AbReas SFlu VisSpat V-MS Lang |
| Hall et al., 2001  [3] | 0 | 75 | 19 | 1 | range:  75-85 | VEM PIQ | VEM PIQ | VEM PIQ | VEM PIQ | VEM PIQ | **VEM** PIQ | **VEM** PIQ | **VEM** PIQ | **VEM** PIQ | **VEM** PIQ | **VEM PIQ** | **VEM PIQ** |
| Tierny et al., 2005 [4] | 10y: 216 5y: 474 | 10y: 47  5y: 77 | 10 | 5 | 10y:  75.2 ± 5.7\*\* 5y:  80.0 ± 6.2\*\* |  |  | **VEM** WM AbReas SFlu PFlu Info VisSpat Attn V-MS Lang |  |  |  |  | **VEM** WM AbReas **SFlu** PFlu **Info** VisSpat Attn V-MS Lang |  |  |  |  |
| Saxton et al., 2004 [5] | 621 | 72 | 8 | 1 | 73.7 ± 4.3\*\* |  |  |  |  |  | **VEM** **NVEM** EF SFlu PFlu Info VisSpat Attn V-MS Lang |  |  | **VEM NVEM** **EF** **SFlu** PFlu Info VisSpat Attn V-MS Lang |  | **VEM NVEM EF** **SFlu** PFlu Info VisSpat **Attn** V-MS **Lang** |  |
| Elias et al., 2000 [6] | 937 | 109 | 22 | 2 | 72.5 ± 5.7\*\* |  |  | **VEM** NVEM WM **AbReas** PFlu |  |  |  |  | **VEM** **NVEM** WM **AbReas** PFlu |  |  |  |  |
| Small et al., 1997a [7] | 179 | 26 | 3 | 3 | 83.5 ± 4.7\*\* |  |  |  |  |  |  |  |  |  | **VEM** **NVEM** WMSFlu **PFlu** VisSpat MMSE |  |  |
| Bäckman et al., 2001  [8] | 105 | 15 | 6 | 3 | 82.2 ± 4.71\*\* |  |  |  |  |  |  | **VEM** WM |  |  | **VEM** WM |  |  |
| Chen et al., 2000 [9] | 483 | 120 | 10 | 2 | 75.6 ± 4.6\*\* |  |  |  |  |  |  |  |  |  |  | **VEM** **EF** SFlu PFlu Lang Prax MMSE |  |
| Chen et al., 2001 [10] | 483 | 68 | 10 | 2 | 73.1 ± 4.5\*\* |  |  |  |  |  |  |  |  | **VEM** **EF** SFlu PFlu Lang Prax MMSE |  | **VEM** **EF** SFlu PFlu Lang Prax MMSE |  |
| Jacobs et al., 1995 [11] | 402 | 41 | 4 | 1 | 73.3 ± 6.8\*\* |  |  |  |  |  |  |  |  |  |  | **VEM** NVEM **AbReas** SFlu PFlu VisSpat **Lang** MMSE |  |
| Fabrigoule et al., 1998  [12] | 1134 | 16 | 5 | 2 | not reported (ca. 73 y) |  |  |  |  |  |  |  |  |  |  | **VEM NVEM AbReas SFlu V-MS MMSE** |  |
| Amieva et al., 2005 [13] | 1050 | 215 | 10 | 2 | not reported (ca. 73 y) |  |  |  | **NVEM AbReas SFlu MMSE** |  |  |  |  |  |  |  |  |
| Amieva et al., 2008 [14] | 350 | 350 | 15 | 2.3 | not reported (ca. 73 y) | NVEM AbReas **SFlu** MMSE IADL Dep CogCom |  | NVEM **AbReas** **SFlu** MMSE IADL Dep CogCom | **NVEM** **AbReas** **SFlu** **MMSE** IADL Dep CogCom | **NVEM** **AbReas** **SFlu** **MMSE** IADL **Dep** **CogCom** |  | **NVEM** **AbReas** **SFlu** **MMSE** **IADL** **Dep** **CogCom** |  |  |  |  |  |

\*\* mean ± SD not reported, calculated from text; VEM =Verbal episodic memory; NVEM = Nonverbal episodic memory; WM = Working Memory; EF = Executive functioning (Trail Making Test B); AbReas = Abstract Reasoning; SFlu = Semantic fluency; PFlu = Phonemic fluency; VisSpat = Visuo-spatial ability; V-MS = Visuo-motor speed; Attn = Attention; Info = Information subtest of the WAIS; Lang = Language; eVIQ = Estimated verbal intelligence; Prax = Praxis; PIQ = Performance IQ; MMSE = Mini-Mental State Examination; ADL/IADL; Activities of daily living / Instrumental activities of daily living; A/M/Dep = Affect/Mood/Depression; CogCom = Cognitive Complaints.

References

[1] Grober E, Hall CB, Lipton RB, Zonderman AB, Resnick SM, Kawas C (2008) Memory impairment, executive dysfunction, and intellectual decline in preclinical Alzheimer’s disease. J Int Neuropsychol Soc **14**(2), 266-278.

[2] Masur DM, Sliwinski M, Lipton RB, Blau AD, Crystal HA (1994) Neuropsychological prediction of dementia and the absence of dementia in healthy elderly persons. *Neurology* **44**(8), 1427-1432.

[3] Hall CB, Ying J, Kuo L, Sliwinski M, Buschke H, Katz M, Lipton RB (2001) Estimation of bivariate measurements having di+erent change points, with application to cognitive ageing. *Statist. Med* **20**, 3695–3714.

[4] Tierney MC, Yao C, Kiss A, McDowell I (2005) Neuropsychological tests accurately predict incident Alzheimer disease after 5 and 10 years. *Neurology* **64**(11), 1853-1859.

[5] Saxton J, Lopez OL, Ratcliff G, Dulberg C, Fried LP, Carlson MC, Newman AB, Kuller L (2004) Preclinical Alzheimer disease: neuropsychological test performance 1.5 to 8 years prior to onset. *Neurology* **63**(12), 2341-2347.

[6] Elias MF, Beiser A, Wolf PA, Au R, White RF, D'Agostino RB (2000) The preclinical phase of Alzheimer disease: A 22-year prospective study of the Framingham Cohort. *Arch Neurol* **57**(6), 808-813.

[7] Small BJ, Herlitz A, Fratiglioni L, Almkvist O, Bäckman L (1997) Cognitive predictors of incident Alzheimer’s disease: a prospective longitudinal study. *Neuropsychol* **11**(3), 413-420.

[8] Bäckmann L, Small BJ, Fratiglioli L (2001) Stability of the preclinical episodic memory deficit in Alzheimer’s disease. *Brain* **124**, 96-102.

[9] Chen P, Ratcliff G, Belle SH, Cauley JA, DeKosky ST, Ganguli M (2000) Cognitive tests that best discriminate between presymptomatic AD and those who remain nondemented. *Neurology,* **55**(12), 1847-1853.

[10] Chen P, Ratcliff G, Belle SH, Cauley JA, DeKosky ST, Ganguli M (2001) Patterns of cognitive decline in presymptomatic Alzheimer disease: a prospective community study. *Arch Gen Psychiatry* **58**(9), 853-858.

[11] Fabrigoule C, Rouch I, Taberly A, Letenneur L, Commenges D, Mazaux JM, Orgogozo JM, Dartigues JF (1998) Cognitive process in preclinical phase of dementia. *Brain* **121**(1), 135-141.

[12] Jacobs DM, Sano M, Dooneief G, Marder K, Bell KL, Stern Y (1995) Neuropsychological detection and characterization of preclinical Alzheimer’s disease. *Neurology* **45**(5), 957-962.

[13] Amieva H, Jacqmin-Gadda H, Orgogozo J-M, Le Carret N, Helmer C, Letenneur L, Barberger-Gateau P, Fabrigoule C, Dartigues JF (2005) The 9 year cognitive decline before dementia of the Alzheimer type: a prospective population-based study. *Brain* **128**(5), 1093-1101.

[14] Amieva H, Le Goff M, Millet X, Pérès K, Barberger-Gateau P, Jacqmin-Gadda H, Dartigues JF (2008) Prodromal Alzheimer’s disease: successive emergence of the clinical symptoms. *Ann Neurol* **64**(5), 492-498.